Advances in the Effects of Antiphospholipid Syndrome on Female Infertility and Outcomes of Assisted Reproductive Technologies
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2023.0406
- VernacularTitle:抗磷脂综合征对女性不孕及体外受精-胚胎移植助孕结局的研究进展
- Author:
Man-ning LANG
1
;
Wei-hong LI
1
Author Information
1. Reproductive Medical Center， The First Affiliated Hospital of Chongqing Medical University， Chongqing 400016， China
- Publication Type:Review
- Keywords:
antiphospholipid syndrome;
infertility;
in vitro fertilization and embryo transfer
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2023;44(4):582-586
- CountryChina
- Language:Chinese
-
Abstract:
Antiphospholipid syndrome （APS） is an autoimmune disease characterized by the persistent presence of antiphospholipid antibodies， which are associated with thrombosis and pregnancy-related complications. APS may have adverse effects on female reproductive function by affecting ovarian function， endometrialization， and other mechanisms， and may lead to embryo implantation failure and pregnancy loss during in vitro fertilization and embryo transfer （IVF-ET） treatments. The routine screening and management of APS before IVF-ET in infertile populations remains controversial and requires individualized risk assessment and appropriate management measures to improve the success rate of assisted reproductive technologies （ART） and reduce maternal and fetal risks during pregnancy. This review summarizes the effects of APS on female infertility and outcomes of ART， as well as the management of the population affected by APS， providing new insights for clinical diagnosis and treatment.
